A U.S. based leading pharmaceutical company specialized in topical drugs approached Freyr to file original IND (Investigational New Drug) submissions along with amendments to the USFDA.
To know more about how Freyr managed to handle large volume of submissions and amendments under stringent timelines with zero errors and warnings, read the case study.
Fill the form below to download the Case Study
